Sverige dåligt på att utnyttja kompetens

MVAs genomgång bland biotechbolag visar att de som har lyckats bäst är de som i ett tidigt skede kopplat internationell kompetens till sin styrelse eller advisory board.

Changeable proteins cause nerve disease

An incorrectly folded protein is one of the reasons behind the nerve disease ALS, according to new research. But the protein does not have structural errors all the time and only certain types contribute to the harmful protein accumulations that cause the ALS disease.

BMAs: Run your own business

After graduation you must decide: be an employee or start your own business. This is not really the situation for BMAs today, but a collaborative project between Swedish public actors and some companies aims to change that and make entrepreneurs of BMAs.

From planning stage to handshake

"Partnering is an effective tool to get in touch with the decision makers high up in an organization's administration," says Camilla Huse Bondeson at Conlega. And according to her, rigorous planning is the way to succeed.

Cate Poulsen, Qiagen

Why are you going to Scanlab and Biotech Forum?

Young, bright and committed to labtech

Ghazal Voghoui recently bought her first apartment and finally settled in Stockholm again. Last year, she finished her law studies and she is relieved to be back after living in Geneva for four years. On November 10 she will take a big career leap, becoming the new CEO of Swedish Labtech.

How to get the most out of the fair

Nytt namn i Symphogens ledning

Adriann Sax har utsetts till affärschef på det danska företaget.

The winner of the race

She learned how to work hard at an early age and her devotion has certainly paid off. Whether it is field running or running a company, the key to success is focus according to Yvonne Mårtensson.

Han ger råd till Gothia Forum

Det nya samarbetet kring kliniska studier i väst har fått en ordförande till sin advisory board.

Kattforskare får pris

Jonas Wensman belönas för sin forskning kring en neurologisk sjukdom som främst drabbar utekatter.

Ny ledare till sött bolag

Han ska leda Daniscos affärsområde för sötningsmedel.

Instrument för skräddarsydd behandling snart här

En apparat stor som en mobiltelefon kan komma att revolutionera förskrivningen av läkemedel.

Avhopp i Probis top

Bolagets styrelseordförande lämnar sitt uppdrag.

Acronordic öppnar Stockholmskontor

CRO-företaget vill expandera ut i hela Norden. En säljspecialist och forskare med bred erfarenhet ska leda det nya kontoret.

Major changes to the Q-Med board

The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.

Swedish top scientists to EMBO

Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and one is from the University of Uppsala.

Teams up with leading dermatologist

Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.

Grant for development projects in Gothenburg

Seven research projects receive SEK 1 million to promote commercialization of early drug development and medical technology.

Pfizer lays a chunky bid on Wyeth

The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal

New member to Active board

The Election Committee of Active Biotech proposes a very experienced financial sector executive to join the company board. Five existing members are also to be re-elected at the AGM in May.

New CEO to Promedvi

Sigrun Axelsson has taken on the leadership of the Lund-based medtech company.

Researchers goes to the bottom of the brain

Swedish researchers have recently got new and deeper knowledge about the smallest part of the brain, the granule cells.

EUR 2 million for peanut allergies

ALK Abelló has signed an agreement to invest EUR 2 million in the French biotechnology company DBV Technologies.